Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY 3018250 in Healthy Volunteers
NCT06562985Phase 1Completed
- Sponsor
- Bayer
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of inclocibart (5 arms), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events at 75 days. Started Sep 2024; status: completed.
02
Drugs
inclocibart
Beyond the preview
Go deeper on NCT06562985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562985.